

***Fiscal Year 2025 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525PRMRPCTA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the congressionally directed FY25 PRMRP topic areas and FY25 PRMRP strategic goals. Proposed projects may range from small proof-of-concept trials through large-scale definitive trials. <i>Submission of a Letter of Intent is required prior to full application submission.</i> <i>Clinical trials are required. Animal studies not allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$8.0 million (M) for total costs. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): June 9, 2025 5:00 p.m. Eastern time</p> <p>Application: July 21, 2025 11:59 p.m. Eastern time</p>
<p>Technology/Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525PRMRPTTDA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals. Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. <i>Submission of a Letter of Intent is required prior to full application submission.</i> <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$2.5M for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): June 9, 2025 5:00 p.m. Eastern time</p> <p>Application: July 21, 2025 11:59 p.m. Eastern time</p>